Skip to content
Research Article Open access CC BY 4.0

Pediatric Myocarditis and Pericarditis Complication after mRNA-based COVID-19 Vaccination

Taral K. Parikh

Asian Journal of Pediatric Research · pp. 6–11 · Published 20 Jul 2022

10.9734/ajpr/2022/v9i230261

Abstract

Oyster and co-authors (2022) have authored an article called Myocarditis cases reported after mRNA-based COVID-19 vaccination in the United States from December 2020 to August 2021, which studies and investigates the resulting number of cases of Myocarditis concerning the COVID-19 vaccination for pediatric patients older than 12 years of age but include individuals less than 30 years of age. From analyzing COVID 19 vaccination, there is more attribute towards the benefits associated with health matters as outlined by Bozkurt and co-authors (2021). However, from the research, the vaccination holds potential risks that would harm the population involved (Halushka & Vander Heide, 2021). The article investigates the different reports of Myocarditis and pericarditis rates after mRNA-based vaccination in the United States and globally. With the detailed information, the article has reviewed additional existing knowledge to support the study’s objective. Public health Ontario 2022 also provides an overview of the event of Myocarditis and Pericarditis following mRNA COVID 19 vaccines. Data from other countries also reported Cases of Myocarditis/Pericarditis following immunization with mRNA vaccine in Ontario, Canada, and internationally. Reported cases have occurred more frequently in males under 30 years, following the second dose, usually within one week of vaccination, and have mild with quick recovery. Although they also mention that the benefit of vaccination continues to outweigh the risk of COVID-19 illness, the authority still recommends vaccination for all eligible individuals, including children and youth. Also, per the American college of cardiology, vaccine-associated Myocarditis is a rare but possible side effect after m-RNA based COVID-19 vaccine. The clinical course of this Myocarditis is generally mild, with most symptoms resolving quickly.

COVID 19 vaccine Pediatric Myocarditis Pediatric Pericarditis m-RNA vaccine

References (7)

  1. 1 Myocarditis [DOI]
  2. 2 Myocarditis With COVID-19 mRNA Vaccines [DOI]
  3. 3 Myocarditis after Covid-19 Vaccination in a Large Health Care Organization [DOI]
  4. 4 Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations [DOI]
  5. 5 Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex [DOI]
  6. 6 Coronavirus-induced myocarditis: A meta-summary of cases [DOI]
  7. 7 Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine [DOI]

Cited by 2

Analysis Comparing the Recovery of Airway Reflexes and Cognitive Ability After Sevoflurane with Desflurane Anesthesia

Mohammed Wajid Ali Khan, Prajnyananda Das, V. Bhavani · Journal of Pharmacy and Bioallied Sciences · 2024

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

61

Page views

0

PDF downloads

9

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.